Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00677443 |
Recruitment Status :
Completed
First Posted : May 14, 2008
Last Update Posted : June 14, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary objective :
To compare the combination of S-1 and oxaliplatin(SOX) to the combination of capecitabine and oxaliplatin(COX) therapy for advanced or metastatic colorectal carcinoma.
Secondary objectives :
- To evaluate and compare the efficacy (overall survival and response rate) in the two treatment groups.
- To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer | Drug: S-1 & Oxaliplatin Drug: Capecitabine & Oxaliplatin | Phase 3 |
- The urgent need for new effective therapy with better safety profile for metastatic colorectal cancer patients and promising results observed so far in trials with S-1 combined with oxaliplatin in gastrointestinal cancer including colorectal cancer strongly warrants the comparison of S-1 combined with oxaliplatin to capecitabine combination with oxaliplatin acknowledged as a standard regimen in a first-line treatment for advanced colorectal cancer patients.
- Recently, a Phase I study was completed, indicating recommended dose as S-1 100 mg/m2/day1-14 and oxaliplatin (130 mg/m2/day1), repeated every 3 weeks. However, in the phase II study using the above recommended dose, delayed toxicities of thrombocytopenia and anemia were observed. These delayed toxicities were also reported in a phase II study using S-1 90 mg/m2/day plus oxaliplatin 130 mg/m2/day1 in advanced gastric cancer. At 2007 GI ASCO, the interim data of S-1(80 mg/m2/day1-14) plus oxaliplatin (130 mg/m2/day1) combination, repeated every 3 weeks, was presented, showing promising antitumor activity with favourable safety profile. Among 18 patients, there were only two patients with Grade 3 thrombocytopenia and one with Grade 3 neutropenia. Response rate was 57.1 % and disease control rate was 92.9 %. Considering these results and Japanese data which showed that enhanced efficacy was not observed with S-1 over 90 mg/m2/day and oxaliplatin combination, S-1 80 mg/m2/day 1-14 and oxaliplatin 130 mg/m2/D1, repeated every 3 weeks, will be tested in this study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 344 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer |
Study Start Date : | June 2008 |
Actual Primary Completion Date : | September 2009 |
Actual Study Completion Date : | January 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: S-1 and Oxaliplatin
S-1 and Oxaliplatin S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks |
Drug: S-1 & Oxaliplatin
S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Other Name: S-1 and Oxaliplatin |
Active Comparator: Capecitabine and Oxaliplatin
Capecitabine and Oxaliplatin
|
Drug: Capecitabine & Oxaliplatin
COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Other Name: Capecitabine and Oxaliplatin |
- To compare the combination of S-1 and oxaliplatin to the combination of capecitabine and oxaliplatin in terms of progression free survival in patients previously untreated by systemic therapy for advanced or metastatic colorectal carcinoma. [ Time Frame: 9 months ]
- To evaluate and compare the efficacy (overall survival and response rate) in the two treatment groups. [ Time Frame: 24 months ]
- To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups. [ Time Frame: 24 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically documented colorectal adenocarcinoma
- Age over 18 years old
- Performance status (ECOG scale): 0-2
- Measurable or evaluable disease
- Patients can take food and drugs orally
- Adequate organ functions
- Life expectancy ≥ 3 months
- Patients should sign a written informed consent before study entry
Exclusion Criteria:
- Tumor type other than adenocarcinoma
- Second primary malignancy
- Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) for advanced or metastatic colorectal cancer
- Adjuvant or neo-adjuvant treatment for non-metastatic (M0) disease has been completed within 6 months prior to initiation of study treatment.
- Prior radiotherapy was administered to target lesions selected for this study, or radiotherapy to the non-target lesions has been completed within 4 weeks before randomization.
- Presence of CNS metastasis
- Obvious peritoneal seeding or bowel obstruction disturbing oral intake
- Symptomatic peripheral neuropathy
- Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery. The patient received curative operation or RFA for metastatic disease.
- Serious illness or medical conditions
- Receiving a concomitant treatment with drugs interacting with S-1, capecitabine or oxaliplatin, as follows;flucytosine, a fluorinated pyrimidine antifungal agent phenytoin warfarin etc.
- Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug.
- Pregnant or lactating woman
- Women of child bearing potential not using a contraceptive method
- Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential
- Any patients judged by the investigator to be unfit to participate in the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00677443
Korea, Republic of | |
National Cancer Center | |
Goyang, Gyeonggi, Korea, Republic of, 410-769 | |
Seoul National University Bundang Hospital | |
Seongnam, Gyeonggi, Korea, Republic of | |
Chonnam National University Hospital | |
Hwasun, Jeollanamdo, Korea, Republic of, 519-809 | |
Yeungnam University | |
Daegu, Korea, Republic of, 705-717 | |
Gachon University Gil Medical Center | |
Inchon, Korea, Republic of | |
Samsung Medical Center | |
Seoul, Korea, Republic of, 135-710 | |
Asan Medical Center | |
Seoul, Korea, Republic of, 138-736 | |
Korea Cancer Center Hospital | |
Seoul, Korea, Republic of, 139-706 | |
Soon Chun Hyang University Hospital | |
Seoul, Korea, Republic of, 140-743 | |
Seoul National University Hospital | |
Seoul, Korea, Republic of | |
Yonsei University | |
Seoul, Korea, Republic of |
Study Chair: | Young Suk Park, M.D.,Ph.D. | Samsung Medical Center, Seoul, Korea | |
Principal Investigator: | Hye Jin Kang, M.D.,Ph.D. | Korea Cancer Center Hospital , Seoul, Korea | |
Principal Investigator: | Jee Hyun Kim, M.D.,Ph.D. | Seoul National University Bundang Hospital, Gyeonggi, Korea | |
Principal Investigator: | Tae Won Kim, M.D.,Ph.D. | Asan Medical Center, Seoul, Korea | |
Principal Investigator: | Tae-Yoo Kim, M.D.,Ph.D. | Seoul National University Hospital , Seoul, Korea | |
Principal Investigator: | Dong Bok Shin, M.D.,Ph.D. | Gil Medical Center, Gyeonggi, Korea | |
Principal Investigator: | Joong Bae Ahn, M.D.,Ph.D. | Yonsei Medical Center, Severance Hospital, Seoul, Korea | |
Principal Investigator: | Kyung Hee Lee, M.D.,Ph.D. | Yeungnam University College of Medicine , Daegu, Korea | |
Principal Investigator: | Namsu Lee, M.D.,Ph.D. | Soon Chun Hyang University Hospital , Seoul, Korea | |
Principal Investigator: | Ik-Joo Chung, M.D.,Ph.D. | Chonnam National University Hwasun Hospital, Jeollanamdo, Korea | |
Principal Investigator: | Yong Sang Hong, M.D.,Ph.D. | National Cancer Center, Gyeonggi, Korea |
Responsible Party: | Young Suk Park, M.D.,Ph.D. Professor, Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT00677443 |
Other Study ID Numbers: |
2008-03-012 |
First Posted: | May 14, 2008 Key Record Dates |
Last Update Posted: | June 14, 2013 |
Last Verified: | June 2013 |
metastatic colorectal cancer S-1 Capecitabine Oxaliplatin non-inferiority study |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases |
Intestinal Diseases Rectal Diseases Capecitabine Oxaliplatin Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |